Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.
May Ee PngVictoria HarrisJenna GrabeyNigel David HartBhautesh Dinesh JaniDaniel ButlerAndrew Carson-StevensMaria CoatesLucy CuretonMelissa DobsonJienchi DorwardPhilip H EvansNick A FrancisOghenekome Abisoye GbinigieGail HaywardJane HolmesKerenza HoodSaye H KhooHaroon AhmedMark LownMicheal McKennaSam MortJonathan S Nguyen-Van-TamNajib M RahmanDuncan B RichardsNicholas P B ThomasOliver Van HeckeFrederick David Richard HobbsPaul LittleLy-Mee YuChristopher C ButlerStavros Petrounull nullPublished in: The British journal of general practice : the journal of the Royal College of General Practitioners (2024)
At the current cost of £513 per course, molnupiravir is unlikely to be cost-effective relative to usual care over a 6-month time horizon among mainly vaccinated patients with COVID-19 at increased risk of adverse outcomes, except those aged ≥75 years.